Plato Investment Management Ltd Acquires 422 Shares of Veeva Systems Inc. $VEEV

Plato Investment Management Ltd increased its holdings in Veeva Systems Inc. (NYSE:VEEV) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,047 shares of the technology company’s stock after buying an additional 422 shares during the period. Plato Investment Management Ltd’s holdings in Veeva Systems were worth $2,022,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of VEEV. Crossmark Global Holdings Inc. bought a new stake in shares of Veeva Systems during the 1st quarter worth $299,000. Private Trust Co. NA lifted its stake in Veeva Systems by 35.0% in the first quarter. Private Trust Co. NA now owns 247 shares of the technology company’s stock worth $57,000 after purchasing an additional 64 shares during the last quarter. Merit Financial Group LLC lifted its stake in Veeva Systems by 12.5% in the second quarter. Merit Financial Group LLC now owns 45,247 shares of the technology company’s stock worth $13,030,000 after purchasing an additional 5,042 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Veeva Systems by 15.7% in the second quarter. QRG Capital Management Inc. now owns 12,771 shares of the technology company’s stock worth $3,678,000 after purchasing an additional 1,735 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Veeva Systems by 9.3% in the second quarter. Nordea Investment Management AB now owns 391,273 shares of the technology company’s stock worth $110,832,000 after purchasing an additional 33,378 shares during the last quarter. 88.20% of the stock is owned by institutional investors.

Veeva Systems Price Performance

VEEV stock opened at $291.20 on Monday. The company has a market capitalization of $47.73 billion, a PE ratio of 59.80, a P/E/G ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a 12 month low of $201.54 and a 12 month high of $310.50. The firm’s 50-day moving average is $285.22 and its 200 day moving average is $272.91.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.90 by ($0.64). The company had revenue of $789.08 million during the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Sell-side analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling at Veeva Systems

In other Veeva Systems news, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the transaction, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. This trade represents a 12.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the transaction, the insider directly owned 25,325 shares in the company, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 24,665 shares of company stock valued at $7,438,000. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on VEEV shares. Piper Sandler boosted their price objective on shares of Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, August 28th. KeyCorp boosted their price objective on shares of Veeva Systems from $285.00 to $325.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. Evercore ISI boosted their price objective on shares of Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a research note on Thursday, August 28th. Citigroup upped their target price on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Finally, Morgan Stanley raised their target price on shares of Veeva Systems from $210.00 to $222.00 and gave the company an “underweight” rating in a research note on Thursday, August 28th. Seventeen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Veeva Systems currently has an average rating of “Moderate Buy” and an average target price of $307.58.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.